BACKGROUND: Palmar-plantar erythrodysesthesia syndrome (PPES) is an uncommon side effect of high-dose cytarabine or methotrexate. Prior case reports of PPES have been limited, and the predisposing factors for the development of PPES remain unknown. METHODS: A review of databases identified 22 patients (1.3%) who developed 39 episodes of PPES among 1720 patients after treatment with high-dose cytarabine or methotrexate. RESULTS: Symptoms lasted a mean of 6.4 days. Hands and feet were both involved in 68% of the initial episodes. Parenteral opioids were required for pain control by 27% of the patients. In comparison with the 1698 children treated with similar therapy, the children who developed PPES were older (mean age at diagnosis, 14.3 vs 7.7 years; P 5 7.5 3 10 -7 ). The frequency of PPES was less common in patients receiving methotrexate alone (7 of 946 or 0.7%) versus cytarabine (7 of 205 or 3.4%; P 5 .005) but was not different for those receiving both high-dose methotrexate and cytarabine (8 of 569 or 1.4%; P 5 .32). Prolonged infusions of methotrexate were associated with less frequent PPES in comparison with rapid infusions (P 5 1.5 3 10 -5 ), as was the co-administration of dexamethasone with cytarabine (P 5 2.5 3 10 -6 ). Self-described race and sex were not associated with PPES. In a multivariate analysis, older age and high-dose cytarabine administration without dexamethasone remained associated with PPES (P 5 1.1 3 10 -4 and P 5 .038, respectively). A genome-wide association study did not identify any associations with PPES meeting the genome-wide significance threshold, but top variants were enriched for skin expression quantitative trait loci, including rs11764092 in AUTS2 (P 5 6.45 3 10 -5
INTRODUCTION
Survival after the diagnosis of childhood cancer has steadily increased over the last 30 years, partly because of improvements in supportive care that have allowed the administration of higher doses of chemotherapy. 1 Among the toxicities that have accompanied these higher doses of therapy, there is palmar-plantar erythrodysesthesia syndrome (PPES), also called hand-foot syndrome or chemotherapy-induced acral erythema, 2 a dermatologic toxicity typically affecting the palmar aspects of the hands and the plantar aspects of the feet. 3 Patients who experience PPES suffer redness, swelling, pain, and sometimes desquamation of the affected skin. 4 PPES is rare in pediatrics. Although the largest pediatric case series involved treatment with pegylated liposomal doxoribucin, 5 prior case reports suggest that it is most common after the administration of high-dose cytarabine or methotrexate, 2-4,6-10 possibly because these 2 agents are used more frequently. PPES appears to be more prevalent in adults than children, 9 although the reason for this difference is unknown. Notably, although hand-foot syndrome has also been used to describe the relatively common hyperkeratosis that develops on pressure points with the use of multikinase inhibitors, this side effect is pathologically distinct from PPES due to cytotoxic chemotherapies. 11 Here, we report a case series of 22 patients who developed PPES after treatment with either high-dose cytarabine or high-dose methotrexate. We examine predisposing factors in these patients and describe the incidence of recurrence with ongoing therapy. Finally, we demonstrate the challenges of using genome-wide association studies (GWASs) to identify genetic predispositions for rare complications of cancer care.
MATERIALS AND METHODS

Patient Selection
St. Jude therapeutic protocols were selected on the basis of chemotherapy regimens likely to cause PPES due to the inclusion of high-dose cytarabine (500 mg/m 2 /dose) or high-dose methotrexate (1 g/m 2 /dose; requiring leucovorin rescue). Patients treated on the AML02 12 and AML08 (NCT00703820) protocols for acute myeloid leukemia received high-dose cytarabine, whereas patients on OS08 (NCT00667342) were treated for osteosarcoma with high-dose methotrexate. Patients on SJBCII (NCT00187161) and SJBCIII (NCT01046825) were treated for mature B-cell lymphoma/leukemia with both high-dose methotrexate and high-dose cytarabine. Patients treated for acute lymphoblastic leukemia on TOTAL13a 13 and TOTAL13b 14 received high-dose methotrexate. Finally, patients treated for acute lymphoblastic leukemia on TOTALXIV (NCT00187005), TOTALXV (NCT00137111), 15 and TOTALXVI (NCT00549848) were treated with high-dose methotrexate and, in the case of standard-and high-risk patients, high-dose cytarabine. All grade 2 or higher nonhematological toxicities were recorded in protocol adverse-event databases, which were reviewed at the time of the data freeze (November 20, 2013) to identify grade 2 or greater skin or soft tissue toxicities. Medical records were then reviewed to confirm the presence of PPES and to document the course and interventions provided. Reports of hand or foot pain also prompted a medical record review unless the pain was reported to be neuropathic. Patients were considered cases if they experienced both pain and erythema (equivalent to grade 2 or higher according to the Common Terminology Criteria for Adverse Events, version 4.0) and the treating clinician diagnosed the patient with PPES. Patients were excluded if the rash was vesicular or associated with viral stomatitis. Patients treated with kinase inhibitors before the onset of the rash were also excluded. The duration of symptoms was measured from the onset of pain and/or erythema to the resolution of physical findings and the completion of therapeutic interventions targeting PPES. Controls for the GWAS were selected for genotyping in a 3:1 ratio and were matched for the treatment, age, and self-identified race.
All patients older than 18 years and parents of minors consented to a pharmacogenetic analysis. Minors provided age-appropriate assent. All parents/participants in clinical trials provided consent/assent for treatment consistent with the Declaration of Helsinki. The clinical trials and this study were approved by the institutional review board.
Ancestry Determination
Patient's self-described ancestry was categorized as white if the patients declared that they were non-Hispanic white, black if they described themselves as black or African American, and other for all others. The genetic ancestry for genotyped patients was determined with STRUCTURE (version 2.2.3), as previously described. 16 When ancestry was treated as a categorical variable, individuals were classified as white, black, or other according to their inferred genetic ancestry as follows: those with >90% Northern European ancestry (CEU) were classified as white; those with >70% West African ancestry (YRI) were classified as black; and those not classified as white or black, including Asians (those with >90% east Asian ancestry [CHB/JPT]) and Hispanics (those with Native American ancestry > 10% and percentage Native American ancestry > the percentage of West African ancestry), were categorized as other.
Genotyping and GWAS Quality Control
Germline DNA was obtained from peripheral blood mononuclear cells after appropriate consent. For leukemia patients, samples were obtained after remission; for solid tumor and lymphoma patients, samples were obtained when peripheral blood leukocyte counts were adequate for sample collection. DNA was genotyped on the Illumina Human Exome BeadChip (version 1.1 or 1.2) as well as Affymetrix GeneChip Genome-Wide Human SNP Array 6.0.
Genotyping results for patients were excluded if the call rate for the patient was <95%. Single-nucleotide polymorphisms (SNPs) were excluded if their call rate was <95% or if they were in Hardy-Weinberg disequilibrium (P < 1 3 10 -4 ) in ancestral whites. SNPs with a minor allele frequency of less than 0.5% were excluded. To reduce false discovery due to the small sample size, only SNPs in which the minor allele was associated with an increased risk of PPES were included.
Statistical Analysis
Patient characteristics were tested for associations with the development of PPES with a chi-square test for univariate analyses and with an analysis of variance for multivariate analyses with R (version 3.2.2). 17 SNPs were evaluated for associations with PPES after adjustments for genetic ancestry with a logistic regression implemented in PLINK (version 1.90b3.38). 18 To evaluate possible functional effects of the top-ranked SNPs, the association of SNP genotypes with gene expression was evaluated in GTEx queried tissues at P < .05 were considered expression quantitative trait loci (eQTLs).
RESULTS
Patient Characteristics
A total of 1720 patients were enrolled in the trials described previously; they included 946 patients who received only high-dose methotrexate, 205 patients who received only high-dose cytarabine, and 569 patients who received both high-dose methotrexate and high-dose cytarabine. There were 39 episodes of PPES in 22 patients (1.3% of patients; mean, 1.8 episodes per patient; range, 1-4 episodes per patient; Table 1 ). The mean duration of the first episode was 5.8 days (range, 2-16 days), and the mean duration of subsequent episodes in the 11 patients with more than 1 episode was 6.8 days (range, 2-14 days); the mean duration of all episodes was 6.4 days. Initial episodes involved both the hands and feet in 15 patients (68%), only the hands in 4 patients, and only the feet in 3 patients.
Cytarabine was the implicated drug in 23 events (14 cases), and methotrexate was implicated in 16 events (11 cases), although 2 patients (2 events) also received intermediate-dose cytarabine (100 mg/m 2 intravenously daily) along with high-dose methotrexate during the course before PPES onset. Although 7 cases were exposed to both high-dose cytarabine and high-dose methotrexate during separate courses of therapy, only 3 had PPES after both drugs. Although high-dose cytarabine has previously been implicated in PPES, 3 events in 3 patients occurred after intermediate-dose cytarabine (without methotrexate). All 3 of these patients had experienced prior episodes after high-dose cytarabine. Patients received a total of 54 courses of similar therapy (ie, high-dose methotrexate or cytarabine) after their first episode and experienced recurrent PPES symptoms in 14 (26%). In the univariate analysis, PPES occurred less commonly in patients receiving methotrexate alone (0.7%) versus cytarabine alone (3.4%; P 5 .005), but the rate was similar to the rate for those receiving both drugs (1.4%; P 5 .32; Table 2 ). Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BCL, mature B-cell leukemia/lymphoma; IV, intravenous; OS, osteosarcoma. a Recurrence indicates the number of times that palmar-plantar erythrodysesthesia syndrome returned and the number of times that patients were rechallenged with the same chemotherapy that preceded the initial palmar-plantar erythrodysesthesia syndrome episode. b No genetic material was available; the patient was not included in the genome-wide association study. c Therapy before the onset of palmar-plantar erythrodysesthesia syndrome included high-dose methotrexate (3 g/m 2 over 3 hours) and cytarabine (100 mg/m 2 daily for 5 days).
Original Article
Because cytarabine and methotrexate are administered in different combinations and according to different schedules for different diseases, we evaluated the impact of the methotrexate administration rate and cytarabine coadministration with glucocorticoids on PPES after these drugs. Among patients receiving high-dose methotrexate, PPES was more common (occurring in 2.5% of patients) when methotrexate was infused rapidly (1 g/m 2 /hour) than when it was infused more slowly (0.1% of patients; P 5 1.5 3 10 -5
; Table 2 ). Among patients receiving highdose cytarabine, PPES was less common when dexamethasone was administered with cytarabine (0.2%) than when cytarabine was given without glucocorticoids (5.2%; P 5 2.5 3 10 -6
; Table 2 ). In the univariate analysis, older age was the only demographic feature associated with PPES (mean for cases, 14.3 years; mean for controls, 7.7 years; P 5 7.5 3 10 -7 ). There was no sex difference in the frequency of PPES, with 1.6% of females and 1% of males symptomatic (P 5 .39). The PPES frequency was similar across patients of different self-declared races, with 1% of whites, 2% of blacks, and 2.5% of patients of other races having symptoms (P 5 .16).
In the multivariate analysis, older age (P 5 1.1 3 10 -4 ) and cytarabine administration without dexamethasone (P 5 .038) were associated with higher rates of PPES, whereas a faster methotrexate infusion rate trended toward a higher rate of PPES (P 5 .065; Table 2 ).
Therapeutic Interventions
Twenty-eight episodes in 15 patients required treatment with oral opiates, and 9 episodes in 6 patients required parenteral opiates for symptom control. Gabapentin was prescribed to 4 patients (9 episodes). Antihistamines were given to 5 patients (6 episodes), whereas 7 patients (9 episodes) received systemic steroids to treat their symptoms (Table 1) . In 1 episode, no new interventions were prescribed; however, that patient had previously been prescribed oral opioids for disease-related pain, and that patient required oral opioids in 2 subsequent episodes.
GWAS
In a GWAS adjusted for ancestry, no SNPs reached the genome-wide significance threshold of 5 3 10 -8 . There were 10 SNPs representing 8 genetic regions associated with the development of PPES at P < 1 3 10 -4 ( Fig. 1 and Table 3 ). The top SNP was rs4799679, an intronic SNP within CCDC178 (G risk allele frequency, 0.4 for cases and 0.07 for controls; P 5 1. ; OR, 10; 95% CI, 3.1-34). Variants related to folate metabolism were also weakly associated with PPES, with an A risk allele frequency in rs803446 (intronic in MTHFD1L) of 0.38 for cases and 0.22 for controls (P 5 .03; OR, 2.8; 95% CI, 1.1-7.3). Interestingly, 12 of the top 50 SNPs in the GWAS were eQTLs in sun-unexposed skin; they included SNPs in COX7C, AUTS2, NISCH, and HRH2. In contrast, only 1 of the top 50 SNPs was an eQTL in the liver, and only 2 were eQTLs in Epstein-Barr virus-transformed lymphocytes (P < .01 for both).
DISCUSSION PPES is a rare but distressing side effect that results in significant morbidity in patients receiving high-dose methotrexate or cytarabine. Because of its rarity (the largest pediatric case series to our knowledge yet published contained 6 patients receiving pegylated liposomal doxorubicin, 5 whereas the largest case series with conventional cytotoxic agents included only 2 patients 9 ), limited information is available on its risk factors, natural history, and prognosis. Herein, we report the largest case series to date of PPES after these agents, the largest case series in pediatrics, and describe its risk factors. Within our population, 18 of 22 patients (82%) required treatment with opiates for pain relief, and almost a quarter of episodes (9 of 39 episodes [23.1%] in 6 of 22 patients [27.3%]) required admission for parenteral pain management. Importantly, although PPES is a rare event in children, symptoms recurred in half of our population with subsequent courses of therapy, and more than 25% of subsequent courses were complicated by PPES. Thus, the risk of recurrence is high. In our study, patients treated with high-dose cytarabine experienced PPES more frequently than those treated with high-dose methotrexate (P 5 .005). Interestingly, differences in administration appear to alter the risk of PPES. A more rapid infusion of methotrexate appears to increase the risk of PPES by 25-fold (2.5% vs 0.1%), perhaps because of the greater tissue penetration associated with the higher peak concentrations associated with rapid infusion, 20 although this effect was attenuated in the multivariate analysis. This suggests that patients with solid tumors receiving methotrexate may be more likely to develop PPES than patients with leukemia because of their tendency to receive more rapid infusions to achieve higher peak levels in their tumors. 21 Other chemotherapy administered coincidently with cytarabine may also alter the risk of PPES. Of the 7 patients with acute myeloid leukemia developing PPES, 4 developed it while receiving clofarabine in addition to high-dose cytarabine, and this is consistent with prior reports of an increased risk of PPES with this combination. 22 Notably, 2 of these patients had a recurrence of their PPES during later exposure to cytarabine alone, and this indicates that their symptoms were not dependent on their exposure to clofarabine.
Our data also suggest that dexamethasone may diminish the risk of PPES when it is co-administered with high-dose cytarabine (PPES in 5.2% of the patients treated with cytarabine without dexamethasone and in 0.2% of the patients when it was administered with dexamethasone; P 5 2. 5 3 10 -6 ). This is consistent with prior case-series reports suggesting that dexamethasone may prevent the recurrence of PPES due to vinorelbine 23 and pegylated doxorubicin. 24 Although leukocyte-mediated inflammation does not appear to play a major role in the pathogenesis of PPES, 11, 25 it is possible that the anti-inflammatory properties of dexamethasone contribute to this effect. Although our data suggest that dexamethasone may be effective in reducing PPES due to cytarabine, we are unable to provide evidence for its role in methotrexate-associated PPES because those therapies were not combined in any of the treatments that we evaluated.
The relative rarity of PPES makes a genomic analysis of its predisposition challenging. No genetic variants in our analysis reached the genome-wide significance level of 5 3 10 -8 . There are multiple possible explanations for this finding. The first is that, despite the screening of a large population of patients for the development of PPES through adverse-event databases, the limited number of identified cases provided insufficient power to detect causal variants. The relative rarity of PPES in this population suggests either that there is little genetic basis for this toxicity or that causative variants are relatively rare or have modest effect sizes. Our study suggests that multiple variants are likely to be contributory because no individual variant accounting for all cases was identified. In addition, half of the patients experienced a recurrence of their symptoms while receiving further therapy, but only 25% of future courses were complicated by PPES. This suggests that there are unidentified nongenetic modifiers altering the risk of developing PPES, which may vary relatively rapidly (ie, they can change between courses of therapy). For example, a 14-year-old receiving methotrexate for osteosarcoma had a recurrence of PPES during 3 of the 7 courses of therapy after her initial episode ( Table 1 ). The limited sample size may also have limited our ability to identify associations between additional clinical factors and the development of PPES. The validation of these clinical and genetic findings in additional cohorts is needed.
Despite these limitations, our study provides interesting insights into possible genetic risk factors for PPES in children. Patients carrying the G risk allele in rs11764092, intronic in AUTS2, were significantly more likely to develop PPES than were patients with the TT genotype (P 5 6.45 3 10 -5 ; OR, 15). This SNP has previously been shown to be an eQTL in skin; patients with the variant G allele had lower expression of AUTS2 in their skin. Interestingly, AUTS2 has previously been shown to be expressed at lower levels in skin from older donors in comparison with skin from younger donors. 26 Because PPES is also seen more commonly in adults 11 and, in our study, older children, gene-age interactions in AUTS2 expression may combine to contribute to PPES. It also suggests that the effect of AUTS2 variants may be less apparent in an adult oncology cohort, in which AUTS2 expression has already decreased because of aging. This is the first study to evaluate the clinical and genetic predisposing factors for developing PPES with methotrexate or cytarabine exposure and to examine this side effect in children. The only prior GWAS evaluating PPES was among adults receiving capecitabine for either breast or colon cancer; in that study, 111 patients across 2 cohorts developed PPES. 27 That analysis was further supplemented by a GWAS of SNPs conferring sensitivity to capecitabine in vitro. Our GWAS was unable to replicate the findings of this prior work, and this suggests that the risk variant previously identified is either age-or capecitabine-specific and did not influence the development of PPES after methotrexate or cytarabine (P 5 .55 for rs9936750 in our data). However, our power was limited by the small sample size. The top SNPs identified in our analysis were not among the 16 SNPs identified in the prior analysis, and this suggests that replication of our genetic findings in an appropriate cohort is needed.
In conclusion, the rarity of PPES limited our power to identify predisposing factors. Nevertheless, we showed for the first time that older age predisposes individuals to PPES within the pediatric population. Our evaluation of genetic features suggests that this toxicity is not monogenic but rather results from an interaction of patient characteristics (eg, age), genetic predispositions (eg, variants in skin eQTLs that alter skin susceptibility to therapy), and therapy schedule (eg, methotrexate infusion time and cytarabine co-administration with dexamethasone). Further studies will be required to extend these findings to the identification of interventions for minimizing this rare but troubling toxicity.
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